[1-(4-methylpyridin-2-yl)propyl]amine dihydrochloride
- $45 - $173
- Product name: [1-(4-methylpyridin-2-yl)propyl]amine dihydrochloride
- CAS: 1158736-00-5
- MF: C9H14N2
- MW: 150.22
- EINECS:
- MDL Number:MFCD18205870
- Synonyms:[1-(4-methylpyridin-2-yl)propyl]amine dihydrochloride;1-(4-methylpyridin-2-yl)propan-1-amine;1-(4-methyl-2-pyridinyl)-1-propanamine(SALTDATA: FREE);1-(4-Methylpyridin-2-yl)propan-1-aMine dihydrochloride;1-(4-Methyl-2-pyridinyl)-1-propanamine;2-Pyridinemethanamine, α-ethyl-4-methyl-
4 prices
Selected condition:
Brand
- ChemBridge Corporation
- Crysdot
- Matrix Scientific
- TRC
Package
- 50mg
- 500mg
- 1g
- ManufacturerChemBridge Corporation
- Product numberBB-4032948
- Product description1-(4-methyl-2-pyridinyl)-1-propanamine 95%
- Packaging1g
- Price$70
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11344891
- Product description1-(4-Methylpyridin-2-yl)propan-1-aminedihydrochloride 95+%
- Packaging1g
- Price$173
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number060299
- Product description[1-(4-Methylpyridin-2-yl)propyl]aminedihydrochloride
- Packaging500mg
- Price$158
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM322048
- Product description1-(4-Methyl-2-pyridinyl)-1-propanamine
- Packaging50mg
- Price$45
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
ChemBridge Corporation | BB-4032948 | 1-(4-methyl-2-pyridinyl)-1-propanamine 95% | 1g | $70 | 2021-12-16 | Buy |
Crysdot | CD11344891 | 1-(4-Methylpyridin-2-yl)propan-1-aminedihydrochloride 95+% | 1g | $173 | 2021-12-16 | Buy |
Matrix Scientific | 060299 | [1-(4-Methylpyridin-2-yl)propyl]aminedihydrochloride | 500mg | $158 | 2021-12-16 | Buy |
TRC | M322048 | 1-(4-Methyl-2-pyridinyl)-1-propanamine | 50mg | $45 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|